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sidoides, an African geranium, for effective supplemental therapy. The second study performed research on the
use of three unique traditional Chinese medicine (TCM) formulations as supplemental therapy for stable
COPD. While the results of both studies reflect data that indicates that these herbal supplements are effective
in extending the length of duration between acute exacerbations, and decreasing the length of acute
exacerbations, further research is necessary to increase confidence in their use.
Conclusion: Use of herbal therapies such as P. sidoides and TCM are promising modalities to maintain
wellness in patients with stable COPD when used as a supplement to baseline therapy for COPD to delay
progression of disease.
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Abstract   
 
Background: Patients with chronic obstructive pulmonary disease (COPD) 
experience progressive pulmonary decline with each acute exacerbation of 
disease. Current therapy is focused on treating acute symptoms of COPD, but 
there are no medications that have been implemented to delay the progression of 
the disease. Herbal therapies have been developed by researchers to supplement 
baseline therapy for COPD with the goal of prolonging healthful pulmonary 
states, thereby slowing disease progression.  
 
Methods:  Exhaustive search of available medical literature from Medline, 
CINAHL, Web of Science, EBMR and NIH websites was conducted using the 
keywords: COPD, herbal therapy, and treatment outcomes.  
 
Results:  The search produced nine articles for evaluation. Two articles were 
chosen that met the inclusion criteria of this systematic review. Both studies are 
randomized controlled trials, which support the use of herbal remedies as a 
supplement to baseline COPD therapy. One study investigated the use of 
Pelargonium sidoides, an African geranium, for effective supplemental therapy. 
The second study performed research on the use of three unique traditional 
Chinese medicine (TCM) formulations as supplemental therapy for stable COPD. 
While the results of both studies reflect data that indicates that these herbal 
supplements are effective in extending the length of duration between acute 
exacerbations, and decreasing the length of acute exacerbations, further research 
is necessary to increase confidence in their use. 
 
Conclusion: Use of herbal therapies such as P. sidoides and TCM are promising 
modalities to maintain wellness in patients with stable COPD when used as a 
supplement to baseline therapy for COPD to delay progression of disease. 
Further studies are necessary to evaluate the efficacy of herbal therapy with 
greater control of concomitant factors as well as those patients with etiologies of 
COPD that are not related to smoke inhalation. 
 
Keywords:  Pelargonium sidoides, traditional Chinese medicine, COPD, herbal therapy, 
treatment outcomes 
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Herbal Therapy and COPD: Delaying Onset and 
Duration of Acute Exacerbations with 
Supplementation to Baseline Therapy 
BACKGROUND  
Herbal supplements have been vigorously researched for solutions to 
countless medical ailments and conditions, yet many have weak evidence to 
support their efficacy and safety. Recent studies 1-4 with the use of herbal 
therapies for URI’s and acute bronchitis have had promising results. It is with 
these results that research has recently been focused at not only combatting acute 
illness in patients with COPD, but also their use and efficacy for the protection of 
patients with stable COPD. The use of P. sidoides and TCM are two such 
therapies that have promising evidence that herbal therapies are effective as 
supplemental therapy to baseline medical treatments for better maintenance of 
stable COPD. 
COPD is the fourth leading cause of death worldwide, claiming 2.9 
million people annually, and 40.8 deaths per 100,000 in the US as of 2010. 5,6 
Patients with stable COPD experience decreased lung function with each acute 
exacerbation of the disease. 7-9 The use of herbal therapies for treatment of acute 
respiratory infections has had promising outcomes in recent clinical trials. 1-4 
However, there have been no reviews that evaluate the efficacy of herbal therapy 
for maintenance of stable COPD in the context of intervals between and duration 
of acute exacerbations.  
Patients with stable COPD have a variety of causes for their conditions. 
Smoking, pollution and dusty workplace environments are the most widely 
acknowledged causes of obstructive respiratory damage. However, there are 
populations of patients who have developed COPD simply due to frequent, 
severe respiratory infections during childhood, and still others are afflicted due 
to a systemic deficiency of alpha-1 antitrypsin.  Inasmuch as there is progressive 
research to combat the progression of COPD through pharmaceuticals, 10,11 it is 
imperative that patients who suffer from COPD protect their lungs from any 
further damage, namely through the discontinuation of tobacco inhalation and 
avoidance of pollutants in the air and dusty work environments. Additionally, 
these patients greatly benefit from regular vaccinations for influenza and 
pneumococcal infections. 12 Patients afflicted with alpha-1 antitrypsin disease do 
have the option of IV augmentation therapy of alpha-1 proteinase; 13 however, 
this therapy option is invasive, carries with it exorbitant costs and is oftentimes 
not a feasible treatment option. 
COPD, even in its stable state, presents with ongoing symptoms of cough, 
dyspnea, shortness of breath, and sputum production. When affected with an 
acute exacerbation of the disease, patients relate that they experience an 
amplification of these same symptoms, which can be devastating to their quality 
of life, oftentimes leading to pneumonia, extended hospitalizations and 
ultimately death. 7 
There is evidence that the use of herbal supplements such as Echinacea, 
Baptisia, Thuja and P. sidoides are effective as stand-alone treatments or in 
combination with vitamin and mineral supplements such as zinc, selenium, and 
vitamin C in the treatment of acute bronchitis, the common cold, and asthma. 1-4 
There is some consideration that these herbal therapies may have a role to play in 
managing stable COPD. 
The use of Pelargonium sidoides 14 and traditional Chinese medicine 15 
preparations are showing protective benefits of the respiratory tract as well as 
increasing the functions of the lungs. 
Many view herbal supplementation as a more natural option for their 
medical conditions, and that it is safer to augment their modern drug therapies 
with natural products rather than adding an additional drug to their health 
regimen.  
Current drug therapy offered to patients with COPD is a combination of 
medications that are designed to relax airway smooth muscle (SABA’s and 
LABA’s), dilate bronchioles (ipratropium bromide) and reduce pulmonary 
inflammation (roflumilast, budesonide, theophylline).  Hypercapneic and 
hypoxic patients who have decreased lung compliance receive additional relief 
through the administration of cannulated O2.  12,16 
Recommended drug therapies carry with them multiple adverse affects 
that can cause co-morbidities such as heart palpitations, new onset arrhythmias, 
vocal cord changes, candida infections and narrow therapeutic indices can cause 
drug levels to quickly become toxic. These medications are also implicated in 
exacerbating pre-existing conditions such as diabetes, cardiac dysrhythmias and 
interfere with treatment of other immune system diseases. 11 For those patients 
who have exhausted all medical treatment options, the final treatment option is 
lung transplant, 12 a highly effective, yet risky and extremely invasive procedure 
that is pursued by few patients for resolution of COPD.  
The purpose of researching additional layers of control over COPD is due 
to the importance of protecting existing pulmonary function. Better control of 
acute exacerbations delays deterioration of respiratory function, prolongs higher 
scores of quality of life, reduces higher costs associated with hospitalizations and 
decreases the possibility of developing antibiotic resistance in afflicted patients 
due to frequent antibiotic prescription. 7 In essence, better control of COPD 
reduces the burden of disease in individuals as well as the healthcare 
community. 5,7,8,17  
Current guidelines have been designed to maintain a stable disease state 
and decrease symptoms that interfere with everyday activities in patients with 
COPD. 12 Additionally, patients are encouraged to employ lifestyle modification 
and encourage healthier practices such as smoking cessation, annual influenza 
vaccinations and pneumococcal vaccines every 5 years, employing safety 
measures in the home and workplace to protect the lungs from further damage 
(eg discontinuing use of solid fuel indoors for cooking, protecting miners’ 
respiratory tracts while working, etc.) and environmental modifications such as 
relocating to a region where air pollution is less severe. 18  
Unfortunately, there are patients who are not able to modify their 
lifestyles, such as patients with alpha-1 antitrypsin deficiencies who require 
specialized therapy which includes invasive IV augmentation weekly for the rest 
of the patient’s life, 13 and those who have COPD due to damage caused by 
recurrent childhood respiratory infections. Others who are unable to modify 
their lifestyles live in regions where relocating away from pollution or 
environmental causes is not possible (eg patients in polluted urban areas, with 
no place to move) and still others who have a long history of nicotine addiction 
who are unable to comply with measures offered to discontinue smoking. All of 
these patients are individuals who need to have an additional measure of 
protection over their respiratory systems, to offset or even curtail the onset of 
acute exacerbations from their chronic disease. 
Does the addition of herbal therapy to baseline treatment of stable COPD 
patients delay the onset of acute exacerbations compared to baseline therapy 
alone? 
METHODS 
An Exhaustive literature search was conducted using the following search 
engines: Medline, CINHAL, EBMR, Web of Science, NIH and UpToDate.  
The searches were conducted on the other aforementioned databases with the 
keywords COPD, herbal therapy and treatment outcomes.  
 Criteria used to assess the quality of evidence was conducted through the 
GRADE system. 19 Biases and quality of evidence were evaluated for each of the 
following study outcomes: Extension of time between exacerbations, decrease in 
duration of AECOPD (see figure I), FEV1 measurement, and improvement of 
quality of life pertaining to health/pulmonary symptoms. Each of the 
aforementioned outcomes was evaluated for limitations, indirectness, 
imprecision and inconsistency in the studies’ methodologies, documentation and 
evaluation of data and reporting of results of each study. Scores assigned for 
each outcome of interest ranged from high to very low, and the culmination of 
the evidence was then interpreted to generate an overall grade of evidence 
produced by the studies that were conducted and evaluated.   
Eligibility criteria 
Eligibility criteria for this review were studies conducted on male and 
female adult patients ≥18 years old, on patients clinically diagnosed with COPD, 
on the use of herbal therapy as augmentation to baseline treatment of stable 
COPD, evaluating of pulmonary function through spirometry, in the English 
language, on research sample size >30 participants and as a randomized 
controlled trial study design. 
Exclusion criteria  
Exclusion criteria included patients suffering from asthma, acute 
bronchitis/acute exacerbation of COPD, studies that included acupoint and 
acupuncture methods, and studies that evaluated pulmonary function through 
biomarkers found in blood.  
 
RESULTS  
A total of nine studies were included in the original search for studies that 
were relevant to this review. Two studies 14,15 were identified that applied 
supplemental herbal therapy to recommended baseline medications in male and 
female human adult patients with stable COPD (See Figure II) 20. Both studies are 
randomized controlled trials and are available in the English language.  
Pelargonium sidoides trial 
Researchers recruited 200 male and female patients over the age of 18 
years in 18 medical centers from the regions of Kiev and Lugansk in Ukraine 
who were suffering from stage II or stage III COPD (FEV1 <80% and >30%) for a 
twenty-four-week treatment study.  
Researchers screened all volunteers with initial measurements of FEV1 
before the use of ipratropium bromide/fenoterol, and again at least 6 hours post 
dose. Chest x-rays and common COPD symptoms such as cough, sputum 
production and chest pain were also assessed before acceptance into the study. 
Patients were considered eligible at the time of the trial’s initiation only if their 
rise in FEV1 was less than or equal to 0.31 after 2 puffs of ipratropium 
bromide/fenoterol inhalation dosed at least 6 hours earlier. Patients were also 
required to be free from concomitant respiratory infections, and had been free 
from AECOPD over the past 4 weeks, were free of other systemic chronic 
diseases and had not used concomitant medications that could interfere with the 
baseline therapy that was to be offered. 14  
Patients included were randomized into double-blind controlled groups 
to evaluate the efficacy of supplementation of P. sidoides to baseline COPD 
therapy of salmeterol and ipratropium bromide/fenoterol for patients with 
COPD II and budesonide was added for patients who were diagnosed with 
COPD III. 14  
Randomization software generated the medication number lists as well as 
the patient allocation lists by a researcher not involved with the clinical aspect of 
the study. All patients received their medications in a prospective manner from a 
pharmacist who allocated the medications according to the numbered list 
provided for the study. 14  
Baseline therapy was distributed to all patients in the study according to 
their stage of COPD outlined by GOLD criteria. Patients allocated to the herbal 
therapy group were instructed to ingest 30 drops of P. sidoides suspension three 
times daily for 24 weeks in addition to baseline therapy. The therapeutic 
preparation was a combination of P. sidoides root extract, suspension fluid (1:8-
10) and 11% ethanol. Patients in the placebo group also received baseline therapy 
and were provided a matched preparation that was to be orally ingested three 
times daily for 24 weeks. 14  
Patients were instructed to return for screening at weeks 4, 8, 12, 16, 20, 
and 24. The investigators prescribed supplemental prednisolone and augmentin 
or ofloxacin if patients in either group presented with symptoms that required 
aggressive therapy for bacterial infections throughout the course of the study. 14  
The primary endpoint of this research was to observe an increase in time 
to the first exacerbation of COPD after therapy had ensued.  Patients were 
directed to record their use of medications and symptoms in a daily diary to 
track compliance and features of their health status. The authors acknowledged 
that it is difficult for patients to recall the date of their last exacerbation before the 
trial therapy began, and it is common for patients to fail to report to a physician 
for each exacerbation of their disease. Therefore, the researchers performed an 
adaptive interim analysis that allowed for a sample size of 200 or more patients 
to provide sufficient power to achieve the study aim. 14 
 Secondary endpoints of interest were number and duration of mild and 
moderate exacerbations during treatment, as well as a comprehensive health 
status score from the St. George’s Respiratory Questionnaire 21 and patient 
satisfaction scores. 14 
Use of P. sidoides as baseline supplemental treatment led to an average of 
57 days between AECOPD, as compared to the average of 43 days experienced 
by patients receiving placebo therapy. Furthermore, patients in the treatment 
group saw a decrease in length of exacerbations by one day; herbal therapy 
patients had an average of 11 days of AECOPD, whereas patients receiving 
placebo experienced 12 days of AECOPD. Measurement of FEV1 in the treatment 
group reflected an increase in baseline values that were approximately 3% higher 
than those of patients in the placebo group who received baseline COPD therapy 
alone. 14  
Adverse events identified with the use of P.sidoides were primarily minor 
gastrointestinal discomfort, which was reported by fifty-one patients in the 
therapy group who experienced seventy-nine events of minor gastrointestinal 
disorders. The placebo group reflects that forty-six patients reported forty 
adverse events. 14  
Mean duration of treatment was 168 days and compliance to the trial was 
nearly 100% in both groups. One patient was lost to follow up from the herbal 
therapy group. Each patient’s allocation to the different analysis populations was 
defined prior to unblinding. This allowed for further evaluation of any data that 
may have skewed results due to non-compliance of study subjects. 14  
Traditional Chinese Medicine therapy 
Researchers conducted a randomized controlled trial with a total of 352 
male and female patients between the ages of 40-80 years in 4 separate medical 
centers in China over the course of 18 months who had been diagnosed with 
mild to severe COPD, as determined by GOLD guidelines and Chinese 
Treatment Guidelines of COPD. 15  
Patients who met the above demographics were screened and included in 
the study if diagnostic criteria of both GOLD and Chinese Treatment Guidelines 
of COPD were met as well as the following inclusion criteria: the patient 
underwent a 2 week washout period prior to the commencement of therapy, had 
not participated in any other interventional trials within the past month, and 
were amenable to treatment as volunteers who were able to sign informed 
consent. Blood, urine and stool specimens were obtained for routine screening. 
Further testing was also employed for liver and kidney function, and an EKG 
was also performed at the onset of therapy as well as at the six-month 
evaluation. 15 
By applying Traditional Chinese medicine theory to the evaluation of 
patients, further exploration of each patient’s physical symptoms was required 
for allocation to subsets of the herbal therapy group. Patients were defined as 
having lung-spleen qi deficiency, lung-kidney qi deficiency, or lung-kidney and 
yin deficiency. 15  
Each subset of lung deficiencies were defined through evaluation of the 
patient’s respiratory symptoms, energy levels, gastrointestinal symptoms, weight 
changes, characteristics of pulses, musculoskeletal symptoms, hearing and 
balance issues, genitourinary symptoms, varying levels of diaphoresis, and the 
appearance of their tongues. 15  
Jiang Yin Tian Jiang Pharmaceutical Company produced the three TCM 
formulations following appropriate protocols, which were tested against 
required quality standards. Bu-Fei Jian-Pi (BFJP) granules were formulated and 
packaged for patients suffering from lung-spleen qi deficiency. Bu-Fei Yi-Shen 
(BFYS) granules were formulated and packaged for patients suffering from lung-
kidney qi deficiency. Yi-Qi Zi-Shen (YQZS) granules were formulated and 
packaged for patients suffering from lung-kidney and yin deficiency. 15  
Randomization software was used to allocate patients to treatment and 
placebo groups. Allocation was documented, sealed and held by an independent 
clinical statistician. Patients were assigned on a one to one ratio to the control 
group or experimental group to which their condition matched. Each of these 
patients was also supplied with baseline medications for COPD according to 
GOLD guidelines. Those patients in the placebo group were provided with 
baseline therapy alone. There were 176 patients in the control group who 
received baseline medication as placebo and 176 total patients receiving TCM 
and baseline medication. 15  
Baseline therapy was supplied to all participants in the study. The 
researchers revealed that this was an open-label trial; however, several measures 
were employed to strengthen the quality of the study. Such measures involved 
appointing an investigator who was separate from the research team at each 
research center to preserve and record the randomization information for the 
study, the clinical researchers had no effect on enrollment or randomization, and 
outcome assessments of the patient’s health were performed by independent 
clinical statisticians who were blinded to group allocation and were uninvolved 
in providing intervention or management of patient’s health outcomes. 15  
The dosing of baseline therapies was assigned according to the stage of 
COPD outlined by GOLD criteria. Those patients who also received herbal 
supplementation were issued bags of TMC granules ranging in weights from 
3.83g to 5.16g. The variation in weights corresponds to the TCM subsets to which 
each patient was assigned (ie BFJP for lung-spleen qi deficiency, BFYS for lung-
kidney deficiency, and YQZS for lung-kidney qi and yin deficiency). Each patient 
in the TCM therapy group was instructed to ingest three bags of granules orally 
twice daily for six months in addition to baseline medical therapy. 15  
Patients presented at 0, 6 months, 12 months and again at 18 months in 
order that exacerbation frequency, exacerbation duration, lung health (measured 
by FEV1 and FVC) and symptomatology might be assessed and evaluated by a 
clinician. The party responsible for recording AECOPD duration and frequency 
between study visits were not clearly identified if performed by a researcher or 
the patients themselves. 
Primary endpoints for this study were AECOPD, measured as an average 
number of exacerbations over the course of 6 months, duration of AECOPD, and 
lung function measured as FEV1. 15 
Secondary endpoints were evaluated on a point scale of symptoms, 
exercise tolerance, and health status outcomes. 15  
There was a large group (44 patients) who did not complete the full course 
of the trial; however, the researchers employed two data sets to reflect the results 
of those patients who were compliant to the study’s design, and those who were 
exposed to one or more treatments of therapy. In this way, the researchers of the 
TCM trial were fully aware of the risk of publication bias and addressed this 
issue directly through additional data sets that represented all patients  
involved. 15 
The data collected reveals that the patients in the treatment groups who 
received any one of the three granular formulations as a supplement to baseline 
medical therapy experienced an average of 0.54 exacerbations over the course of 
6 months as compared to placebo, which experienced an average of 1.06 
exacerbations over the same time frame. 15  
Additionally, patients in the treatment group saw a decrease in average 
days of exacerbations (4.39 therapy, 6.37 placebo). At the 18 month re-evaluation, 
patients in the treatment group continued to show healthier FEV1 values on 
average (+4.16ml/year therapy, -52.54ml/year placebo), longer 6MWD on average 
(31.84meters therapy, 14.07meters placebo), and a greater average in quality of 
life (13.26% therapy, 6.13% placebo), 15 which was measured with the WHOQOL-
BREF questionnaire. 22 
Patients in the trial did report 5 adverse events associated with the 
combination of baseline treatment and herbal therapy. All five patients 
experienced different adverse events including: abdominal distention, 
palpitations, constipation, thirst, and insomnia. 15  
The control group also reported 8 adverse events associated with therapy. 
Each patient also experienced different adverse events including: abdominal 
distention, palpitations, constipation, thirst, insomnia, stomach discomfort and 
dry throat. 15 
Three hundred-six patients completed the experiment, with 46 patients 
being released from the study due to poor compliance or loss to follow up. The 
researchers developed a Per protocol analysis set of results for those patients 
who were the most compliant to therapy. Additionally, a full analysis set was 
constructed to evaluate those patients who were included into the study and 
were observed on at least one record point during the trial. For those clinical 
visits where information was partially missing, the principle of last visit carried 
out was applied. A safety set was also developed for those patients who took the 
trial medicine at least once. 15  
 
DISCUSSION 
 Patients with stable COPD are faced with the stark reality that the disease 
they are plagued with is progressive and mostly irreversible. 7 While there are 
baseline therapies of beta agonists, inhaled corticosteroids, theophylline and 
supplemental oxygen for the various symptoms of mild to severe COPD, the 
only method to truly reverse COPD is lung transplantation. 12 However, in an 
effort to slow the progression of the disease for those who are not reasonable 
candidates for transplant, guidelines direct clinicians to emphasize the need for 
smoking cessation, avoidance of indoor solid fuel pollution, and dusty work 
environments and regular vaccinations. Unfortunately even with patients 
modifying their lifestyles and utilizing their recommended medications, they 
find that with each acute exacerbation of the disease, their symptoms take longer 
to resolve, they tend to fall ill more frequently, and their quality of life 
deteriorates.  
Use of herbal therapies for treatment of respiratory infections has become 
a well-researched topic of interest across the globe. Multiple reviews have been 
performed that have evaluated the efficacy of herbal therapy during acute 
exacerbations of COPD 23-25, yet there are limited data that has been produced 
pertaining to supplemental treatment of stable COPD. Clinicians are trained to 
encourage patients to engage in healthful life choices as well as taking 
preventative measures to maintain wellness. The population of patients with 
COPD would benefit from additional preventative therapy to maintain their 
stable disease state.  
Clinical Relevance 
The evidence provided in this review reflects that there are herbal 
remedies that have shown to be effective in prolonging stable states of COPD 
and shortening the length of acute exacerbations. 14,15 These two studies 14,15 were 
designed to address these issues. Data sets were obtained in both studies that 
primarily assessed patients who had been diagnosed with COPD due to smoking 
and inhalation of excessive air pollution. Patients suffering from COPD due to 
genetic variations or early childhood disease were not assessed as thoroughly as 
possible. Additionally, there are other herbs that have been researched and have 
some promising results for treatment of acute respiratory exacerbations such as 
Echinacea, Byronia, and Ginseng. 1,2,26-28 These herbs may be additional 
interventions that may add an additional level of protection to the respiratory 
systems of patients with COPD. 
The results of this review can be used clinically as a suggestion for 
patients with stable COPD who are motivated to protect their health and slow 
the progression of the disease.  
Both herbal therapies evaluated in this review show promising results for 
the prolongation of stable COPD. Results from both trials reflect that the 
combined use of baseline medical therapy and adjunct herbal therapy decreases 
the number of exacerbations per year as compared to placebo. 14,15 P. sidoides 
shows an increase in days between exacerbations to be an average of 12 days 
longer than placebo. 14 TCM shows a decrease in the average number of acute 
exacerbations per year of 0.97 exacerbations per 6 months compared to 1.48 
exacerbations per 6 months experienced by placebo. 15  
Additionally, patients are experiencing decreases in duration of acute 
exacerbations. P. sidoides showed an average decrease in length of exacerbations 
to drop from twelve days to eleven days. 14 TCM reveals that patients receiving 
this therapy experience an average of 2 days less of symptoms, a reduction from 
6.37 days to 4.39 days per exacerbation. 15  
Both studies also reflect increases in measurements of FEV1 and decreases 
in symptom severity during AECOPD.  
Limitations of Study 
Each study was evaluated for risk of bias and quality of evidence through 
the use of the GRADE system. 19 Both studies reflected a degree of bias and lack 
of specificity in the evidence reported.  
The study evaluating P. sidoides 14 reflects reporting bias due to the lack of 
raw data that was crucial to display strength in the quality of evidence of the 
paper, earning it a grade of low quality of evidence.  
Instead of using the average number of days to acute exacerbation and 
duration of acute exacerbation, the researchers provided the median number of 
days. Additionally, each patient’s FEV1 was recorded at each visit (days 0, and 
weeks 4, 8, 12, 16, 20, and 24); however, raw data of these recordings are not 
included in the published results.  Patients included in this study were asked to 
document their COPD symptoms, health status and use of study medications as 
well as any other supplementary medications over the course of the six-month 
study in a daily diary. Reporting bias is likely in this aspect of the research, as 
each patient may have developed a different evaluation scale of his or her 
symptoms. Reporting bias appears to be present also due to the lack of data and 
confidence intervals provided in the paper for all endpoints other than the 
primary. This may have in turn led to a lack of precision, due to the unreported 
data that is relevant for this study. 14  
Although the authors state that the sample populations were statistically 
equivalent, the patients in the placebo group appeared to have had the likelihood 
of being sicker due to smoking status and gender imbalance. Additionally, 
baseline FEV1 measurements after 6 months reflected an average of 3% increase 
in the herbal therapy sample, however, it was not commented on by the 
researchers, and may be a source of underreporting error. 14  
The study of TCM reflects bias in the development of the study’s 
methodologies due to the nature of an open-label study, and a failure to report 
meaningful data. Due to these flaws this study earned a grade of low quality of 
evidence. 15 
The paper identifies that the research was conducted as an open-label 
study, and several levels of blinding were implemented by the designers of the 
study, however, there is still a level of reporting bias that is likely to come from 
the patients, as they knew which therapy they were receiving throughout the 
trial. It is possible that the patients divulged their group allocation to the clinical 
evaluator who assessed their health at each clinical encounter. 15  
The TCM study 15 also failed to provide data for all secondary endpoints, 
which reduced the quality of evidence from high to moderate due to the 
likelihood of recall bias through the omission of these data. The TCM study was 
also a study involving three sets of unique herbal therapies. The outcomes of all 
three of the regimens were compiled and presented in the study, thereby 
omitting conclusive data for each formulation’s strength or weakness in 
treatment. 15  
Furthermore, both studies are weak in their patient population focus. Each 
study included patients who were diagnosed with COPD, yet the stages of 
COPD varied from mild to severe in one study, 15 and was limited to Sages II and 
III in the other. 14 The study of TCM 15 limited the patient population to those who 
were 40-80 years of age, a limit that was likely to omit those patients who are 
suffering from COPD due to sources other than smoke inhalation. Additionally, 
patients with COPD secondary to smoke inhalation were also identified for 
specific statistics in the published outcomes. However, patients with other 
etiologies of COPD were not acutely evaluated, as were the patients with COPD 
secondary to smoke inhalation. Both studies did not indicate whether the 
patients involved in the trials had previously been using baseline therapy for 
their COPD. This omission of information also decreases the strength of the data 
collected, due to the variability of outcomes for patients who may have been 
exposed to any type of therapy for the first time while participating in this trial.  
Variability across studies was seen through the preliminary methods 
employed before the study began, and also before the measurement of 
pulmonary function.  The TCM 15 trial required a washout period of 2 weeks 
before the initiation of therapy, yet it is unclear if the washout was only for 
respiratory system medications or all medications. The P. sidoides 14 trial 
measured and documented spirometry both before and at least 6 hours after 
inhalation of ipratropium bromide/fenoterol.  
CONCLUSION 
  COPD is a destructive and oftentimes progressive pulmonary disease 
that is currently only treated symptomatically while in its stable stage. When 
patients experience frequent acute exacerbations, their course of disease is 
accelerated with irreversible reductions in lung function as an unfortunate 
outcome. Herbal therapies such as P. sidoides and TCM are formulations that 
have promising outcomes in delaying the onset of new exacerbations and 
reducing the duration of acute exacerbations. Data collected from both studies 
indicate that there is efficacy in these therapies; however, the data provided are 
not robust enough to investigate the breadth of efficacy for all patients who 
suffer from COPD. Additionally, there are multiple confounding factors that 
complicate the clarity of therapy and treatment efficacy; it is possible that these 
factors alone or combined may have manifested a level of bias that affects results. 
Ultimately, it is in the best interest of patients to have another weapon in their 
arsenal to slow the progressive nature of COPD. Herbal therapies may be a new 
treatment on the horizon that will protect the lungs today and maintain their 
health for years to come.  
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Characteristics of Reviewed Studies, GRADE Profile 
 
 
 
FIGURE I 
 
Decrease in duration of AECOPD after 6 months of herbal therapy with TCM or P. sidoides. 
 
 
 
 
 
 
 
 
Quality Assessment 
 Downgrade Criteria 
No. of Studies Design Limitations Indirectness Imprecision Inconsistency Publication bias likely 
Frequency of Acute Exacerbations 
2 
 2 RCT 
Serious 
limitations 
Serious 
indirectness 
No serious 
imprecision 
No serious 
inconsistencies Bias likely 
Duration of Acute Exacerbations 
2 2 RCT  
No serious 
limitations 
No serious 
indirectness 
No serious 
imprecision 
No serious 
inconsistencies No bias likely 
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